I AM NOT A FINANCIAL ADVISER! This is my attempt to better understand the cause/effect relationship of FDA Advisory Committee (AdComm) meetings on BioTech/Pharm stocks. This is for my own education, not to serve to advise or recommend any path for others. If looking for advice look elsewhere. If trying to understand the same stuff I’m trying to understand, please draw your own conclusions… mine are nuts, and would likely put you in the poor house.
- I wish this didn’t have such a “salesman” feel… I hate the “pitchiness” of PR appearances
- Tight timeline for approval… FDA vote was scheduled for about 2 weeks after AdComm
- While the CTO has sold quite a few shares recently, the CFO, COO and VPHR have bought (fairly small positions) in the past 4 months
|Date||Open||High||Low||Close||Change from Prior|
|4/1/2014||Halted for AdComm!
After-Hours trading reached 9.65
- There was a 7.115% drop on the Close of the Materials Release date from the prior Close… materials were released during the trading day.
- There was a brutal 16.77% drop on the Close of the day before AdComm.
- After-hours trading on the date of the Approval vote climaxed at 9.65, for a 140% bump on the Close from the day before AdComm.
- The first Open after the Approval Recommendation was up 94.03%… within two minutes it maxed out at 8.08, or 101.0% over the previous Close.
- The first trading day post-vote High was 4.258% higher than the Open, and occurred within the first two minutes of trading.
- The first trading day post-vote Low was 11.871% lower than the Open.
- The first trading day post-vote Close was 9.806% lower than the Open.
- The five-day High was 4.258% higher than the five-day Open, and occurred on the first day.
- The five-day Low was 22.968% lower than the five-day Open, and occurred on the forth day.
- The actual HIGH was in After-Hours of the afternoon of the vote, at over 9.65, or 140% higher than the previous Close… After-hours is a pretty terrific exit point.